We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA GRANTS IVAX FIRST-FILER STATUS ON GENERIC GLUCOVANCE
FDA GRANTS IVAX FIRST-FILER STATUS ON GENERIC GLUCOVANCE
February 24, 2004
Ivax has received final FDA approval to market a version of Bristol-Myers Squibb’s (BMS’) Type 2 diabetes drug Glucovance (glyburide/metformin HCl), the firm said Feb. 19.